Wnt signaling as a regulator of memory T cells: implications for CAR-T cell therapy - Takeaways - MDSpire

Wnt signaling as a regulator of memory T cells: implications for CAR-T cell therapy

  • By

  • Tatiana Fourfouris

  • Ki Jun Lee

  • Samantha Hurwitz

  • Asher Ahdoot

  • Alexander Lee

  • Maiah Zarrabi

  • Michael Kahn

  • Yong-Mi Kim

  • May 13, 2026

Share

  • 1

    CAR-T therapy shows high remission rates in hematologic malignancies but suffers from limited long-term effectiveness due to poor CAR-T cell persistence.

  • 2

    Wnt/β-catenin signaling, through TCF1 and LEF1, regulates memory programming essential for CAR-T cell longevity and positive patient outcomes.

  • 3

    Activation of the Wnt/β-catenin pathway promotes the development of CD8+ memory stem cells, enhancing their proliferative and recall capabilities.

  • 4

    Genetically modified CAR-T cells are influenced by the same mechanisms that govern memory development in endogenous T cells, linking basic biology to CAR-T engineering.

  • 5

    Wnt-targeted strategies have clinical potential to improve CAR-T cell memory phenotypes, persistence, and reduce exhaustion in cancer therapies.

Original Source(s)

Wnt signaling as a regulator of memory T cells: implications for CAR-T cell therapy

  • by Tatiana Fourfouris, Ki Jun Lee, Samantha Hurwitz, Asher Ahdoot, Alexander Lee, Maiah Zarrabi, Michael Kahn, Yong-Mi Kim

  • May 13, 2026

Related Content

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants

Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American...

Unique Phase I NSCLC Trial Sites Decreasing in United States

The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant conso...